For example, S100A4 was frequently amplified in PAAD and was associated with poor patient survival outcomes, consistent with findings from previous studies (Matsubara et al., 2005; Li and Bresnick, 2006). This evidence concerns the gene S100A4 and pancreatic adenocarcinoma.